BIOLOGICAL · Unmapped registry intervention
rgp120/HIV-1MN
Find medicine records ·
Find other trials using this name
Clinical trial
A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults
NCT00001031
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
BIOLOGICAL · Unmapped registry intervention
rgp120/HIV-1 SF-2
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
HIV Infectionsunresolved
Interventions
rgp120/HIV-1MNBIOLOGICAL
rgp120/HIV-1 SF-2BIOLOGICAL
Sponsors & collaborators
Biocinecollaborator
Genentech, Inc.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00001031 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.